Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports.

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Zymeworks (NasdaqGS:ZYME) with a Outperform ...

Zymeworks Inc (ZYME) navigates a challenging year with strategic pivots and robust partnership earnings, despite increased ...

Capital, LLC EcoR1, a director at $ZYME, bought 468,356 shares of the company on 03-13-2025 for an estimated $5,847,237. This trade was reported by Quiver ...

VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology ...